Banco Bilbao Vizcaya Argentaria S.A. Purchases 102,683 Shares of Kenvue Inc. $KVUE

Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Kenvue Inc. (NYSE:KVUE) by 59.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 274,375 shares of the company’s stock after buying an additional 102,683 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Kenvue were worth $5,739,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Renaissance Capital LLC raised its position in shares of Kenvue by 8.3% during the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after purchasing an additional 48,267 shares during the period. Farther Finance Advisors LLC grew its position in Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after purchasing an additional 16,164 shares during the period. Arlington Partners LLC bought a new stake in Kenvue during the 2nd quarter valued at $2,110,000. Cornell Pochily Investment Advisors Inc. raised its holdings in Kenvue by 144.6% during the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after buying an additional 19,609 shares during the last quarter. Finally, IFP Advisors Inc raised its holdings in Kenvue by 25.3% during the first quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after buying an additional 3,081 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and cut their price target for the company from $22.50 to $22.00 in a research note on Friday, September 26th. The Goldman Sachs Group decreased their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. Barclays raised their target price on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Finally, Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $20.23.

Kenvue Stock Performance

KVUE stock opened at $16.68 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market cap of $31.95 billion, a PE ratio of 22.23, a P/E/G ratio of 2.43 and a beta of 0.71. The business has a 50 day moving average of $16.42 and a 200-day moving average of $20.06. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 5.0%. Kenvue’s dividend payout ratio is presently 110.67%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.